Group One Trading, L.P. Uni Qure N.V. Transaction History

Group One Trading, L.P.

  • $2.68 Billion
  • Q2 2025

A detailed history of Group One Trading, L.P. transactions in Uni Qure N.V. stock. As of the latest transaction made, Group One Trading, L.P. holds 63,681 shares of QURE stock, worth $4.07 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
63,681
Previous 3,545 1696.36%
Holding current value
$4.07 Million
Previous $37,000 2297.3%
% of portfolio
0.03%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025
BUY
$8.34 - $17.27 $501,534 - $1.04 Million
60,136 Added 1696.36%
63,681 $887,000
Q1 2025

May 14, 2025
SELL
$10.6 - $18.08 $1.35 Million - $2.3 Million
-127,304 Reduced 97.29%
3,545 $37,000
Q4 2024

Feb 14, 2025
SELL
$4.54 - $17.73 $105,019 - $410,130
-23,132 Reduced 15.02%
130,849 $2.31 Million
Q3 2024

Nov 14, 2024
SELL
$3.78 - $10.12 $246,690 - $660,451
-65,262 Reduced 29.77%
153,981 $759,000
Q2 2024

Aug 14, 2024
SELL
$4.39 - $5.43 $152,701 - $188,877
-34,784 Reduced 13.69%
219,243 $982,000
Q1 2024

May 10, 2024
BUY
$4.82 - $6.93 $982,055 - $1.41 Million
203,746 Added 405.21%
254,027 $1.32 Million
Q4 2023

Feb 14, 2024
BUY
$5.63 - $8.27 $161,654 - $237,456
28,713 Added 133.13%
50,281 $340,000
Q3 2023

Nov 09, 2023
SELL
$6.71 - $11.83 $1.14 Million - $2.01 Million
-169,609 Reduced 88.72%
21,568 $144,000
Q2 2023

Aug 09, 2023
BUY
$11.12 - $22.2 $2.02 Million - $4.03 Million
181,664 Added 1909.64%
191,177 $2.19 Million
Q1 2023

May 12, 2023
SELL
$18.7 - $23.07 $1.34 Million - $1.65 Million
-71,433 Reduced 88.25%
9,513 $191,000
Q4 2022

Feb 09, 2023
BUY
$18.12 - $27.32 $690,988 - $1.04 Million
38,134 Added 89.07%
80,946 $1.84 Million
Q3 2022

Nov 09, 2022
BUY
$16.98 - $25.54 $10,035 - $15,094
591 Added 1.4%
42,812 $803,000
Q2 2022

Aug 11, 2022
BUY
$13.15 - $20.45 $9,744 - $15,153
741 Added 1.79%
42,221 $787,000
Q1 2022

May 12, 2022
SELL
$14.54 - $21.5 $351,693 - $520,042
-24,188 Reduced 36.83%
41,480 $750,000
Q4 2021

Feb 11, 2022
SELL
$20.24 - $36.01 $963,565 - $1.71 Million
-47,607 Reduced 42.03%
65,668 $1.36 Million
Q3 2021

Nov 12, 2021
BUY
$26.01 - $38.22 $384,895 - $565,579
14,798 Added 15.03%
113,275 $3.63 Million
Q2 2021

Aug 10, 2021
SELL
$29.97 - $37.17 $270,958 - $336,053
-9,041 Reduced 8.41%
98,477 $3.03 Million
Q1 2021

May 12, 2021
BUY
$29.24 - $42.03 $502,957 - $722,958
17,201 Added 19.05%
107,518 $3.62 Million
Q4 2020

Feb 10, 2021
BUY
$35.35 - $50.67 $532,689 - $763,546
15,069 Added 20.03%
90,317 $3.26 Million
Q3 2020

Nov 12, 2020
SELL
$35.98 - $47.66 $313,745 - $415,595
-8,720 Reduced 10.38%
75,248 $2.77 Million
Q2 2020

Aug 13, 2020
BUY
$45.06 - $67.74 $652,288 - $980,604
14,476 Added 20.83%
83,968 $3.78 Million
Q1 2020

May 13, 2020
BUY
$40.01 - $73.97 $1.7 Million - $3.14 Million
42,429 Added 156.78%
69,492 $3.3 Million
Q4 2019

Feb 10, 2020
SELL
$37.13 - $74.62 $225,007 - $452,197
-6,060 Reduced 18.3%
27,063 $1.94 Million
Q3 2019

Nov 12, 2019
BUY
$39.36 - $76.8 $1.3 Million - $2.54 Million
33,123 New
33,123 $1.3 Million
Q2 2019

Aug 09, 2019
SELL
$52.76 - $82.19 $111,640 - $173,914
-2,116 Closed
0 $0
Q1 2019

May 13, 2019
SELL
$27.39 - $68.41 $420,299 - $1.05 Million
-15,345 Reduced 87.88%
2,116 $126,000
Q4 2018

Feb 06, 2019
BUY
$22.8 - $33.93 $10,716 - $15,947
470 Added 2.77%
17,461 $503,000
Q3 2018

Nov 08, 2018
BUY
$29.75 - $43.08 $381,900 - $553,017
12,837 Added 309.03%
16,991 $618,000
Q2 2018

Aug 14, 2018
BUY
$21.96 - $39.94 $91,221 - $165,910
4,154 New
4,154 $157,000

Others Institutions Holding QURE

# of Institutions
191
Shares Held
51.8M
Call Options Held
4.43M
Put Options Held
1.27M
View Full List

About uniQure N.V.

QURE Quotes by TradingView
  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $2.99B
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email